These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38963912)

  • 21. Cortexolone 17α-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0·05% cream.
    Trifu V; Tiplica GS; Naumescu E; Zalupca L; Moro L; Celasco G
    Br J Dermatol; 2011 Jul; 165(1):177-83. PubMed ID: 21428978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of topical clascoterone cream for treatment of acne vulgaris: A systematic review and meta-analysis of randomized placebo-controlled trials.
    Alkhodaidi ST; Al Hawsawi KA; Alkhudaidi IT; Magzoub D; Abu-Zaid A
    Dermatol Ther; 2021 Jan; 34(1):e14609. PubMed ID: 33258536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrated Short-Term and Long-Term Efficacy of Topical Clascoterone Cream 1% in Patients Aged 12 Years or Older With Acne Vulgaris.
    Eichenfield LF; Gold LS; Han J; Hebert AA; Mazzetti A; Moro L; Squittieri N; Thiboutot D
    J Drugs Dermatol; 2024 Jan; 23(1):1278-1283. PubMed ID: 38206145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A New Class of Topical Acne Treatment Addressing the Hormonal Pathogenesis of Acne.
    Barbieri JS
    JAMA Dermatol; 2020 Jun; 156(6):619-620. PubMed ID: 32320045
    [No Abstract]   [Full Text] [Related]  

  • 25. Hypothalamic-Pituitary-Adrenal Axis Response in Patients With Acne Vulgaris Treated With Clascoterone.
    Bhatia N; Eichenfield LF; Mazzetti A; Moro L; Squittieri N; Hebert AA
    J Drugs Dermatol; 2024 Jun; 23(6):433-437. PubMed ID: 38834220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clascoterone: How the Novel Androgen Receptor Inhibitor Fits Into the Acne Treatment Paradigm.
    Purvis CG; Balogh EA; Feldman SR
    Ann Pharmacother; 2021 Oct; 55(10):1297-1299. PubMed ID: 33543640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unmet Needs in the Management of Acne Vulgaris: A Consensus Statement.
    Baldwin H; Farberg A; Frey C; Hartman C; Lain E; Meltzer R; Draelos Z
    J Drugs Dermatol; 2023 Jun; 22(6):582-587. PubMed ID: 37276154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy of Topical Clascoterone versus systematic spironolactone for treatment of acne vulgaris: A systematic review and network meta-analysis.
    Basendwh MA; Alharbi AA; Bukhamsin SA; Abdulwahab RA; Alaboud SA
    PLoS One; 2024; 19(5):e0298155. PubMed ID: 38814916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acne vulgaris: new evidence in pathogenesis and future modalities of treatment.
    Hazarika N
    J Dermatolog Treat; 2021 May; 32(3):277-285. PubMed ID: 31393195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential Role for Topical Antiandrogens in the Management of Acne Among Patients Receiving Masculinizing Hormone Therapy.
    Marks DH; Mansh MD
    JAMA Dermatol; 2020 Dec; 156(12):1380-1381. PubMed ID: 33146681
    [No Abstract]   [Full Text] [Related]  

  • 31. Potential Role for Topical Antiandrogens in the Management of Acne Among Patients Receiving Masculinizing Hormone Therapy-Reply.
    Thiboutot D; Cartwright M; Mazzetti A
    JAMA Dermatol; 2020 Dec; 156(12):1381. PubMed ID: 33146696
    [No Abstract]   [Full Text] [Related]  

  • 32. Long-Term Safety and Efficacy of Twice-Daily Topical Clascoterone Cream 1% in Patients Greater Than or Equal to 12 Years of Age With Acne Vulgaris.
    Eichenfield LF; Hebert AA; Gold LS; Cartwright M; Moro L; Han J; Squittieri N; Mazzetti A
    J Drugs Dermatol; 2023 Aug; 22(8):810-816. PubMed ID: 37556524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of 1% Clascoterone Cream in Patients Aged > 12 Years With Acne Vulgaris.
    Hebert A; Eichenfield L; Thiboutot D; Stein Gold L; Vassileva S; Mihaylova Y; Cartwright M; Moro L; Fragasso E; Han J; Squittieri N; Mazzetti A
    J Drugs Dermatol; 2023 Feb; 22(2):174-181. PubMed ID: 36745367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of acne vulgaris with hormonal therapies in adult female patients.
    Husein-ElAhmed H
    Dermatol Ther; 2015; 28(3):166-72. PubMed ID: 25845307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Guidelines of care for the management of acne vulgaris.
    Reynolds RV; Yeung H; Cheng CE; Cook-Bolden F; Desai SR; Druby KM; Freeman EE; Keri JE; Stein Gold LF; Tan JKL; Tollefson MM; Weiss JS; Wu PA; Zaenglein AL; Han JM; Barbieri JS
    J Am Acad Dermatol; 2024 May; 90(5):1006.e1-1006.e30. PubMed ID: 38300170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contraceptive use in acne.
    Lam C; Zaenglein AL
    Clin Dermatol; 2014; 32(4):502-15. PubMed ID: 25017461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retinoids in Acne Management: Review of Current Understanding, Future Considerations, and Focus on Topical Treatments.
    Chien A
    J Drugs Dermatol; 2018 Dec; 17(12):s51-55. PubMed ID: 30586482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistent acne in women : implications for the patient and for therapy.
    Williams C; Layton AM
    Am J Clin Dermatol; 2006; 7(5):281-90. PubMed ID: 17007539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of tazarotene cream 0.1% after a single dose and after repeat topical applications at clinical or exaggerated application rates in patients with acne vulgaris or photodamaged skin.
    Yu Z; Sefton J; Lew-Kaya D; Walker P; Yu D; Tang-Liu DD
    Clin Pharmacokinet; 2003; 42(10):921-9. PubMed ID: 12885265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acne in the adult female patient: a practical approach.
    Kamangar F; Shinkai K
    Int J Dermatol; 2012 Oct; 51(10):1162-74. PubMed ID: 22994662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.